

December 26, 2024

BSE Limited P J Towers, Dalal Street, Mumbai – 400 001 Script Code: 543904	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: MANKIND	Mankind Pharma Limited 208, Okhla Industrial Area, Phase-III, New Delhi, Delhi- 110020
--	---	--

Dear Sir/ Madam,

Subject: Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (Annexure-I), regarding the change in the shareholding percentage of the promoters and promoters' group of the Company.

The promoters' and promoters' group's shareholding has diluted from 74.87% to 72.71%, reflecting a reduction of 2.16%. This change is consequent upon the allotment of 1,19,04,761 equity shares of face value ₹1 each to eligible Qualified Institutional Buyers (QIBs) under the Company's Qualified Institutional Placement (QIP).

This is for your information and records.

Thanking You,

Yours Faithfully,

**For and on behalf of
Promoters and Promoter Group
of Mankind Pharma Limited**

**Ramesh Juneja
Promoter**

Encl.: A/a

Annexure-I

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Mankind Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	-		
Whether the acquirer belongs to Promoter/Promoter group	-		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t.total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :	29,99,60,612	74.87	74.87
a) Shares carrying voting rights			
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)			
e) Total (a+b+c+d)	29,99,60,612	74.87	74.87
Details of acquisition/sale***	NIL	NIL	NIL
a) Shares carrying voting rights acquired/sold			
b) VRs acquired /sold otherwise than by shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/- d)	NIL	NIL	NIL

After the acquisition/sale, holding of:	29,99,60,612	72.71	72.71
a) Shares carrying voting rights			
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	29,99,60,612	72.71	72.71
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	NA		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	20-12-2024		
Equity share capital / total voting capital of the TC before the said acquisition / sale	40,06,62,138 equity shares of ₹1 each aggregating to ₹40,06,62,138		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	41,25,66,899 equity shares of ₹1 each aggregating to ₹41,25,66,899		
Total diluted share/voting capital of the TC after the said acquisition	41,25,66,899 equity shares of ₹1 each aggregating to ₹41,25,66,899		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) There was no acquisition/sale undertaken by the Promoters and Promoters Group of the Company, the shareholding percentage of the promoters and promoters group of the Company has been changed from 74.87% to 72.71% consequent upon allotment of 1,19,04,761 Equity Shares of face value of ₹1 each on December 20, 2024 to the eligible Qualified Institutional Buyers pursuant to the Qualified Institutional Placement of the Company.

**For and on behalf of
Promoters and Promoter Group of Mankind Pharma Limited**

**Ramesh Juneja
Promoter**